Despite COVID-19, the Company Invests in Wuxi, China – Doubling Its Coating Capacity for Orthopaedic Implants and Adding a Cleaning and Packaging Line

WUXI, China--(BUSINESS WIRE)--Lincotek Medical announces a significant investment in its Chinese manufacturing center in Wuxi, Jiangsu Province. Not only is it doubling its coating capacity for orthopaedic implants, but is also introducing a state-of-the-art cleaning and packaging line – designed and built to the highest standards of the medical industry.

The move comes despite the challenges presented by the coronavirus emergency around the world and demonstrates the Group’s strength and commitment to the Chinese market.

“Being impacted heavily by the Covid-19 crisis, we are very proud of the fast and professional reaction of our Chinese team,” comments Winfried Schaller, CEO of Lincotek Group. “The manufacturing center has coped well, working alongside local authorities to re-open the plant with additional precautions and regulations in place to protect workers and visitors from the virus, while ensuring a continuous supply of high-quality products reflecting our responsibility as a strategic supplier to the medical industry in China.”

In light of this important responsibility, Lincotek Medical, announced today the expansion of its available services through the doubling of its coating capacity with the installation of a second CAPS Intercooler. This cutting-edge technology is Lincotek proprietary coating equipment, widely recognized in the orthopaedic sector for highly advanced porous coatings with unique material performance characteristics and reliable exceptional quality. Doubling CAPS capacity will allow the company to satisfy increasing market demand, while maintaining the highest level of service in terms of reactivity and flexibility. This investment will strengthen Lincotek Medical’s ability to offer to customers global risk mitigation capabilities.

With the new investment, the company will be offering to customers cleaning and packaging services for both temporary and final packaging. This represents another very important step in the integration of new services in the value chain, to provide to our Chinese and APAC customers simplified supply chain solutions, increased efficiency and reduced lead times.

Mark Huguet, General Manager of Lincotek Medical Wuxi said: “In what has been a difficult period, I am very proud, that we are able to announce an important investment in our facility here in China, which will allow us to provide an even higher standard of service and react more quickly to the needs of customers. It shows the level of commitment that Lincotek has to meet the needs of Lincotek Medical’s customer base in China.”

His views were echoed by Gennaro D’Andrea, General Manager of Lincotek Medical Division: “The time ahead is going to bring great challenges for everybody, and we are ready to respond to new trends and demands when the markets begin to recover. The OEMs in the medical market can always rely on us as a trusted partner.”

The priority of Lincotek Medical is to make things easy for the customers and exceed their expectations. The company will keep evolving to provide the best outcome for this market.

About Lincotek Medical. Lincotek Medical, headquartered in Trento, Italy, is a global contract manufacturer for orthopaedic, trauma, spine and dental markets. Lincotek Medical is the medical division of Lincotek, a family-owned Group that has served global markets for more than 45 years. The business has more than 1,100 employees located in 16 production facilities across Europe, North America and Asia. For more information, please visit: lincotek.com

Contacts

Media contact: Francesca Pedrotti, [email protected] | +39 345 6203212